VERACYTE, INC. Form 8-K September 29, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2015

VERACYTE, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-36156 (Commission File Number)

20-5455398 (IRS Employer Identification No.)

7000 Shoreline Court, Suite 250, South San Francisco, California (Address of principal executive offices)

94080 (Zip Code)

Registrant s telephone number, including area code: (650) 243-6300

N/A

(Former name or former address, if changed since last report.)

Edgar Filing: VERACYTE, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:	
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o 240.1	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 4d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: VERACYTE, INC. - Form 8-K

Item 8.01 Other Events.

On September 27, 2015, Veracyte, Inc. (the Company) issued a press release on the preliminary 2016 Clinical Laboratory Fee Schedule determination issued by the Centers for Medicare and Medicaid Services. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release issued by Veracyte, Inc. dated September 27, 2015.

2

Edgar Filing: VERACYTE, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 29, 2015

VERACYTE, INC.

By /s/ Julie A. Brooks

Name: Julie A. Brooks

Title: Executive Vice President and General Counsel

3